Mode
Text Size
Log in / Sign up
N/A N=62 Randomized Other

Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder

Transmission, Blood, Recipient/Donor

Enrolled (actual)
62
Serious AEs
0.0%
Results posted
Apr 2022
Primary outcome: Primary: Plasma Supernatant Hemoglobin — 26.8; 28.0 mg/dL

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
POLFA (Needle Assembly) (Device); Kawasumi (Needle Assembly) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Haemonetics Corporation
Primary completion
Jul 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Plasma Supernatant Hemoglobin
26.8; 28.0

Summary

This study evaluates whether whole blood transferred through the new POLFA needle assembly meets supernatant hemoglobin acceptability standards.

Eligibility Criteria

Eligibility Criteria:

  • Study donor must be ≥ 18 years of age.
  • Study donor must weigh ≥ 110 pounds.
  • Study donor's body temperature must be ≤ 37.5°C / 99.5°F (oral).
  • Study donor's hemoglobin must be ≥12.5 g/dL.
  • Study donor's hematocrit must be ≥ 38%.
  • Study donor must meet all criteria per respective site's Research Blood Donation Record (BDR).
  • Study donor's most recent single RBC unit donation must have been ≥56 days prior to study donation.
  • Study donor's most recent double RBC unit donation must have been ≥ 112 days prior to study donation.
  • Study donor must have consented to study participation by reviewing and having expressed understanding the site-respective IRB-approved informed consent form prior to undergoing any study related procedures.
  • Study donors must agree to report adverse events from the time of signing the informed consent to twenty-four hours following the end of their active study involvement.
  • Study donors must not have experienced any of the following:

Physical trauma consistent with associated coagulopathy within the last 30 days, Surgery within the last 30 days, Known history of hypercoagulopathy (i.e., Factor V Leiden, Prothrombin G20210A, idiopathic venous thrombotic events, etc.).

  • Female study donors must not be pregnant, expected to be pregnant or breastfeeding.

Exclusion Criteria - any individual not meeting the above criteria.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02476851). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search